NCT03807921 is a Phase 4 clinical trial of Warfarin in Aortic Valve Stenosis, sponsored by Instituto Nacional de Cirugia Cardiaca, Uruguay.

Who is sponsoring NCT03807921?

NCT03807921 is sponsored by Instituto Nacional de Cirugia Cardiaca, Uruguay.

What drugs are being tested in NCT03807921?

Interventions in NCT03807921: Warfarin, Aspirin.

What condition does NCT03807921 study?

NCT03807921 studies Aortic Valve Stenosis, Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Valve Regurgitation.

Is NCT03807921 still recruiting?

NCT03807921 is currently completed. Last updated 8 March 2022.

Last reviewed 2022-03-08 · How we verify

NCT03807921

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anticoagulation for Aortic Bioprosthesis (ANTIPRO)

Completed Phase 4 Last updated 8 March 2022

What this trial tests

Phase 4 trial testing Warfarin in Aortic Valve Stenosis in 140 participants. Completed in 31 December 2019.

Timeline

1 January 2019

Primary endpoint
30 December 2019

31 December 2019

Quick facts

Lead sponsor	Instituto Nacional de Cirugia Cardiaca, Uruguay
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	140
Start date	1 January 2019
Primary completion	30 December 2019
Estimated completion	31 December 2019
Sites	2 locations across Uruguay

Drugs / interventions tested

Warfarin (warfarin) — full drug profile →
Aspirin — full drug profile →

Conditions studied

Aortic Valve Stenosis — all drugs for Aortic Valve Stenosis →
Aortic Valve Disease — all drugs for Aortic Valve Disease →
Aortic Valve Insufficiency — all drugs for Aortic Valve Insufficiency →
Aortic Valve Regurgitation — all drugs for Aortic Valve Regurgitation →

Sponsor

Instituto Nacional de Cirugia Cardiaca, Uruguay

Who can join

18 and older, any sex, with Aortic Valve Stenosis or Aortic Valve Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the clinical and hemodynamic outcome in patients after aortic valve replacement. Half of the patients will receive warfarin + aspirin and the other half will receive only aspirin. The investigators will focus mainly on early bioprosthesis degeneration.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Warfarin

Trials testing the same drug.

NCT07502001 — Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin · Phase 1 · not yet recruiting
NCT07456085 — Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves · Phase 3 · enrolling by invitation
NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting
NCT05643651 — Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease · Phase 4 · recruiting
NCT07358416 — Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery. · active not recruiting

Other recruiting trials for Aortic Valve Stenosis

Currently open trials in the same condition.

NCT07455292 — Phenotyping Left Ventricle Failure With Hemodynamic Biomarkers From 4D Flow Magnetic Resonance Imaging · NA · recruiting
NCT07008911 — CardioHeartConnect: Commercially Available Fitness for Cardiac Rehabilitation · NA · recruiting
NCT07145463 — Prospective, Multicenter, Randomized Controlled Clinical Study Evaluating the VitaFlow Liberty® Flex Transcatheter Aorti · NA · recruiting
NCT07520656 — Impact of Transcatheter Aortic Valve Implantation and Mitral Valve Repair on Sleep-Disordered Breathing · recruiting
NCT07267117 — Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease · recruiting

Other Instituto Nacional de Cirugia Cardiaca, Uruguay trials

Trials by the same sponsor.

NCT06496321 — Morbidity of Conventional and No-touch Saphenectomy in Coronary Artery Bypass Grafting. · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03807921 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Instituto Nacional de Cirugia Cardiaca, Uruguay
Last refreshed: 8 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03807921.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing